Ganirelix in insemination cycles of women with premature luteinization

Recombinant FSH (rFSH) treatment with a starting dose of 50-75 IU per day was commenced by the day 3 of menstrual cycle a) according to low dose step-up protocol (Speroff L, Fritz MA (2005). Assisted reproductive technologies. In Clinical Gynecologic Endocrinology and Infertility, 7th ed., pp. 1216–1274) b) by a once daily subcutaneous injection in the abdominal wall, injected by the patient using pen c) until the follicle diameter reach 20 mm (usually within 7-14 days) From day 7 onwards, the gonadotropin dose was adjusted and individualized based on the follicular growth observed by ultrasonography. Ganirelix, GnRH antagonist, was administered a) at the dose of 0.25 mg per day starting from the day in which a follicle > 14 mm in mean diameter was visualized at ultrasound scan (flexible multiple dose protocol) b) by subcutanous injection c) till the follicle reaches 18 mm (usually within 4-5 days)